{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:24Z","timestamp":1791608184668,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess and analyze the visual outcomes of patients with retinal vein occlusions in a real-world setting with a long-term follow-up of more than 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective analysis of 56 patients having retinal vein occlusions from a tertiary eye center, with a mean follow-up of 7 years was performed. Primary outcome measures were mean change in best-corrected visual acuity (BCVA) from baseline at 6 months, 1 year, 2 years, 3 years, and final visit (\u22655 years), proportion of patients having BCVA better than 20\/40 and worse than 20\/200, and mean number of injections. Secondary outcome measures were change in central macular thickness (CMT), development of subsequent retinal vein occlusion (RVO) in same eye or the other eye, and development of neovascular complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The mean change in letter score was + 11.84 in branch RVO (BRVO), +7.14 in non-ischemic central RVO (CRVO), and \u22129.5 in ischemic CRVO at 1 year, which changed to + 8.57, \u22125 and \u2212 24, respectively, at the end of follow-up. CMT had improved from 506 \u00b1 98.8 mm, 576.44 \u00b1 149 mm, and 618 \u00b1 178.27 mm, respectively, at baseline to 267 \u00b1 94 mm, 345.20 \u00b1 122.61 mm, and 265.50 \u00b1 107.75 mm, respectively, in BRVO, non-ischemic, and ischemic hemi RVO (HRVO)\/CRVO groups. The total mean number of injections given in BRVO, non-ischemic CRVO, and ischemic CRVO groups were 4.6, 6.6, and 4.1, respectively. None of the patients with BRVO developed neovascular glaucoma (NVG). Non-ischemic to ischemic HRVO\/CRVO conversion was noted in 4\/11 eyes at a mean duration of 12.6 months. NVG was noted in 7\/9 eyes (77.8%) in initial ischemic CRVO\/HRVO group and 3\/4 (75%) converted eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients with BRVO have good visual outcomes with anti-VEGF, while in CRVO results may vary considerably owing to patient compliance and treatment burden on long-term follow-up in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1330_22","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:53:31Z","timestamp":1670316811000},"page":"4370-4375","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?"],"prefix":"10.4103","volume":"70","author":[{"given":"Payal Naresh","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Palanivelu","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushma Bimal","family":"Vora","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Sirivella","sequence":"additional","affiliation":[{"name":"Sankara College of Optometry, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwetha","family":"Suryakanth","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Jayasingh","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina and Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"R1-20251006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion. A randomized clinical trial. The branch vein occlusion study group","volume":"98","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"R2-20251006","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion:The central vein occlusion study group M report","volume":"102","author":"Clarkson","year":"1995","journal-title":"Ophthalmology"},{"key":"R3-20251006","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion (SCORE) study report 5","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R4-20251006","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion:The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R5-20251006","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R6-20251006","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"R7-20251006","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20251006","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions:Long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20251006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab:The RETAIN study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20251006","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion 52-week results of the VIBRANT study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20251006","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion:18- month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R12-20251006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion:1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R13-20251006","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/bjophthalmol-2014-306543","article-title":"A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion:MARVEL report no. 1","volume":"99","author":"Narayanan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R14-20251006","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","article-title":"Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion:A randomized clinical trial","volume":"137","author":"Hykin","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"R15-20251006","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00417-021-05146-8","article-title":"Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion","volume":"259","author":"de Salles","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-20251006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjophth-2018-000249","article-title":"Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors","volume":"4","author":"Spooner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R17-20251006","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/IAE.0000000000001579","article-title":"Ranibizumab for retinal vein occlusion:Predictive factors and long-term outcomes in real-life data","volume":"38","author":"Chatziralli","year":"2018","journal-title":"Retina"},{"key":"R18-20251006","first-page":"353","article-title":"Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV","volume":"101","author":"Wecker","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R19-20251006","article-title":"Long-term outcomes of anti-VEGF treatment of retinal vein occlusion","author":"Spooner","year":"2021","journal-title":"Eye (Lond)"},{"key":"R20-20251006","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Haller vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion:Six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"R21-20251006","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1097\/IAE.0000000000000191","article-title":"Ranibizumab in preproliferative (ischemic) central retinal vein occlusion:The rubeosis anti-VEGF (RAVE) trial","volume":"34","author":"Brown","year":"2014","journal-title":"Retina"},{"key":"R22-20251006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-019-0183-x","article-title":"Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion","volume":"5","author":"Hall","year":"2019","journal-title":"Int J Retin Vitr"},{"key":"R23-20251006","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0161-6420(83)34542-5","article-title":"Ocular Neovascularization with Retinal Vascular Occlusion-III:Incidence of ocular neovascularization with retinal vein occlusion","volume":"90","author":"Hayreh","year":"1983","journal-title":"Ophthalmology"},{"key":"R24-20251006","doi-asserted-by":"crossref","first-page":"100964","DOI":"10.1016\/j.preteyeres.2021.100964","article-title":"Photocoagulation for retinal vein occlusion","volume":"85","author":"Hayreh","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"R25-20251006","doi-asserted-by":"crossref","first-page":"e0234739","DOI":"10.1371\/journal.pone.0234739","article-title":"Real-world outcomes with ranibizumab in branch retinal vein occlusion:The prospective, global, LUMINOUS study","volume":"15","author":"Pearce","year":"2020","journal-title":"PLoS One"},{"key":"R26-20251006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12886-020-01757-7","article-title":"Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world:Results from an open-label prospective study of Intravitreal Ranibizumab","volume":"21","author":"Narayanan","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"R27-20251006","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.survophthal.2018.04.005","article-title":"Ischemic retinal vein occlusion:Characterizing the more severe spectrum of retinal vein occlusion","volume":"63","author":"Khayat","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"R28-20251006","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41433-020-0861-9","article-title":"A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion","volume":"34","author":"Ang","year":"2020","journal-title":"Eye"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1330_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:05Z","timestamp":1786647545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1330_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1330_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"2022-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}